Prices leak for the rest of Google's new Pixel products
This leak also gives us a $129 price for the Pixel Buds 2A, up a little from the original $99 Buds A-Series, but those launched four years ago. There are some product names and prices for various charging accessories too, including the 'PixelSnap' wireless charging line that's speculated to be Google's Qi2 alternative to Apple's MagSafe. You can see the full pricing leaks and product names below, ahead of everything being officially announced at Google's Pixel event today.
Pixel 10
Pixel 10 Pro
Pixel 10 Pro XL
Pixel 10 Pro Fold
Pixel Watch 4
Pixel Buds 2A: $129
Pixelsnap Ring Stand: $29.99
Pixelsnap Charger: $39.99
Pixel Flex 67W Charger: $59.99
Pixelsnap Charger with Stand: $69.99
Posts from this author will be added to your daily email digest and your homepage feed.
See All by Jess Weatherbed
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Audio
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Foldable Phones
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Gadgets
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Google
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Google Pixel
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Headphones
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Mobile
Posts from this topic will be added to your daily email digest and your homepage feed.
See All News
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Phones
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Smartwatch
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Tech
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Wearable
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Masimo sues US Customs over approval of Apple Watch imports
By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature.
Yahoo
19 minutes ago
- Yahoo
Tesla (TSLA) Stock: Barclays Reiterates Equal Weight, Cites Robotaxi Permit Delays
Tesla, Inc. (NASDAQ:TSLA) is one the . On August 18, Barclays reiterated the stock as 'Equal Weight' stating that it sees a 'lengthy' permitting process for Tesla's robotaxi. 'The process for 'real' autonomous Robotaxi in CA will likely be lengthy, as Tesla must apply for and receive a number of permits prior to offering paid, driverless services; moreover, media reports indicate that Tesla's engagement with California regulators has been more limited than people realize, with Tesla Robotaxi pitched for now in a more limited way than people understand.' Pixabay/Public Domain Analysts on Wall Street currently have a consensus 'Buy' rating on the stock. The average price target of $329 implies a 1.8% upside; however, the Street-high target of $500 implies an upside of 49.2%. Tesla, Inc. (NASDAQ:TSLA) is an automotive and clean energy company that leverages advanced artificial intelligence in its autonomous driving technology and robotics initiatives. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Palantir (PLTR) Stock Under Fire as Citron Warns Valuation Still Too High
Palantir Technologies Inc. (NASDAQ:) is one the . On August 18, Palantir stock received a cautious mention from Citron regarding the company's stock valuation, marking the second time the firm has raised concerns. The stock slipped amid the mention and recent remarks from OpenAI CEO Sam Altman who has warned that the AI market is in a bubble. Altman's remarks have put a question mark over the sustainability of AI-related stock valuations. Previously, the firm led by Andrew Left implied that Palantir may begin to look cheap at $40 per share. However, that view has since been updated, with the analyst now arguing that the stock would remain expensive even at that level. An investor in front of a graph of the U.S. dividend-paying market, looking contemplative. The analysis by the short seller puts OpenAI and Palantir into comparison, highlighting that if Palantir were to trade at the same 17x price-to-revenue multiple as OpenAI (based on Bloomberg consensus estimates of $5.6 billion in 2026 revenue), its implied stock price would be about $40 per share. Citron contends that even this price would mark Palantir as one of the most expensive SaaS stocks. 'OpenAI at $500B Puts Palantir at $40 — And That's Generous ' Another concern that was highlighted is insider selling. The firm noted how CEO Alex Karp has sold nearly $2 billion in Palantir shares over the past two years, which makes him 'one of tech's most aggressive insider sellers.' Palantir Technologies Inc. (NASDAQ:PLTR) is a leading provider of artificial intelligence systems. While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
